



# Foundations of Cardiomtabolic Health Certification Course

Certified  
Cardiomtabolic Health  
Professional (CCHP)



MODULE 7

## Chronic Kidney Disease (CKD)

### IMPORTANT GUIDELINES, STATEMENTS, AND REPORTS:

2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease



KDIGO 2020 Clinical Practice Guideline for- Diabetes Management in Chronic Kidney Disease



KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease



Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022



Management of Chronic Kidney Disease (CKD)- VA/DoD Clinical Practice Guidelines




Guideline on Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease- ACP



National Kidney Foundation: Guidelines & Commentaries





## SUGGESTED READINGS, AND RESOURCES:

Kidney Disease Statistics for the United States



Incidence, Prevalence, Patient Characteristics, and Treatment Modalities



National Trends in the Prevalence of Chronic Kidney Disease Among Racial/Ethnic and Socioeconomic Status Groups, 1988-2016



Epidemiology of Chronic Kidney Disease: An Update 2022



Cardiovascular Risk Prediction Scores in CKD: What Are We Missing?



Kidney Disease, Race, and GFR Estimation



Integrating CKD Into US Primary Care: Bridging the Knowledge and Implementation Gaps



Tolerating Increases in the Serum Creatinine Following Aggressive Treatment of Chronic Kidney Disease, Hypertension and proteinuria: pre-renal success



Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements



Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis



Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician



Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial



Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy



Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): a Randomised, Double-Blind, Crossover Trial



Dapagliflozin in Patients with Chronic Kidney Disease





### SUGGESTED READINGS, AND RESOURCES:

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes



Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study



Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials



Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD



Optimizing Renin-Angiotensin System Inhibitor Use in CKD



Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate



Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes- A meta analysis



Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes



Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes



Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: the FIDELITY Pooled Analysis

